share_log

UBS Upgrades Pacific Biosciences to Buy, Lowers Price Target to $10

Benzinga ·  Nov 17, 2023 07:19

UBS analyst John Sourbeer upgrades Pacific Biosciences (NASDAQ:PACB) from Neutral to Buy and lowers the price target from $13 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment